Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05270460 · ClinicalTrials.gov registry record · Phase 2
Safety, PK and Efficacy of PCS12852 on Gastric Emptying Rate in Patients With Moderate to Severe Gastroparesis
A Phase 2 study, sponsored by Processa Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 25
- Enrollment target
NCT05270460 is a Phase 2 study that has completed, run by Processa Pharmaceuticals. The registered enrollment target is 25 participants.
The verdict
NCT05270460, a Phase 2 study, has completed, sponsored by Processa Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 25 participants
- Enrollment target
Study Summary
This is a randomized, double-blind, placebo-controlled study that will compare the effect of 2 different dosage regimens of PCS12852 on gastric emptying time to placebo in both idiopathic gastroparesis (IG) and diabetic gastroparesis (DG) patients.
Interventions
- DRUG Placebo
- DRUG PCS12852
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2022-03-09 |
| Est. Completion | 2022-10-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05270460
The ClinicalTrials.gov registry entry for NCT05270460 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 25 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Processa Pharmaceuticals, which has 9 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT05270460 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05270460 about?
NCT05270460 is a clinical study titled "Safety, PK and Efficacy of PCS12852 on Gastric Emptying Rate in Patients With Moderate to Severe Gastroparesis". This is a randomized, double-blind, placebo-controlled study that will compare the effect of 2 different dosage regimens of PCS12852 on gastric emptying time to placebo in both idiopathic gastroparesis (IG) and diabetic gastroparesis (DG) patients.
What is the current status of trial NCT05270460?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 25 participants. The study started on 2022-03-09. Estimated completion is 2022-10-06.
What interventions are being tested in trial NCT05270460?
The interventions under investigation include: Placebo (DRUG), PCS12852 (DRUG).
Who is sponsoring clinical trial NCT05270460?
This trial is sponsored by Processa Pharmaceuticals, which has 9 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.